RT Journal Article
T1 Seroreactivity Against Tyrosine Phosphatase PTPRN Links Type 2 Diabetes and Colorectal Cancer and Identifies a Potential Diagnostic and Therapeutic Target
A1 Garranzo Asensio, María
A1 Solís Fernández, Guillermo
A1 Montero Calle, Ana
A1 García Martínez, José Manuel
A1 Fiuza, María Carmen
A1 Pallares, Pilar
A1 Palacios García, Nuria
A1 García Jiménez, Custodia
A1 Guzmán Aránguez, Ana Isabel
A1 Barderas Manchado, Rodrigo
AB Colorectal cancer (CRC) and diabetes are two of the most prevalent chronic diseases worldwide with dysregulated receptor tyrosine kinase signaling and strong co-occurrence correlation. Plasma autoantibodies represent a promising early diagnostic marker for both diseases before symptoms appear. We explore here the value of autoantibodies against receptor-type tyrosineprotein phosphatase-like N PTPRN (full-length or selected domains) as diagnostic markers using a cohort of type 2 diabetic (T2D), CRC, healthy individuals or patients with both diseases. We show that PTPRN autoantibody levels in plasma discriminated between T2D patients with and without CRC. Consistently, high PTPRN expression correlated with decreased survival of CRC patients. Mechanistically, PTPRN depletion significantly reduced invasiveness of CRC cells in vitro and liver homing and metastasis in vivo by means of a dysregulation of the epithelial-mesenchymal transition and a decrease of the insulin receptor signaling pathway. Therefore, PTPRN autoantibodies may represent a particularly helpful marker for the stratification of T2D patients at high risk of developing CRC. Consistent with the critical role played by tyrosine kinases in diabetes and tumor biology, we provide evidences that tyrosine phosphatases such as PTPRN may hold potential as therapeutic targets in CRC patients.
PB American Diabetes Association
SN 0012-1797
YR 2022
FD 2022-03
LK https://hdl.handle.net/20.500.14352/72468
UL https://hdl.handle.net/20.500.14352/72468
LA eng
NO Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
NO Ministerio de Economía y Competitividad (MINECO)/FEDER
NO Instituto de Salud Carlos III (ISCIII)/FEDER
NO Ministerio de Educación
DS Docta Complutense
RD 14 dic 2025